Persistence of use of prescribed cannabinoid medicines in Manitoba, Canada: a population‐based cohort study.

Background and aims: To estimate prevalence of continuous use (persistence) of prescribed cannabinoid medications for up to 1 year from initial prescription in Manitoba, Canada and predictors of duration of use. Design and setting: A retrospective, population‐based, cohort study using administrative...

Descripción completa

Detalles Bibliográficos
Publicado en:Addiction Vol. 114; no. 10; pp. 1791 - 1800
Autores principales: Alkabbani, Wajd, Marrie, Ruth Ann, Bugden, Shawn, Alessi‐Severini, Silvia, Bolton, James M., Daeninck, Paul, Leong, Christine
Formato: research tables/charts Journal Article
Publicado: Wiley-Blackwell Oct2019
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=138498285&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 138498285
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        09652140
        AIO
      jtl: Addiction
      issn: 09652140
      maglogo: Y
    pubinfo:
      dt: Oct2019
      vid: 114
      iid: 10
      pid: 480
      pub: Wiley-Blackwell
      place: Malden, Massachusetts
    artinfo:
      ui:
        138498285
        138498285
        138498285
        10.1111/add.14719
        138498285
      ppf: 1791
      ppct: 9
      formats:
        fmt:
          – @attributes:
              type: T
          – @attributes:
              type: C
          – @attributes:
              type: P
      tig:
        atl: Persistence of use of prescribed cannabinoid medicines in Manitoba, Canada: a population‐based cohort study.
      aug:
        au:
          Alkabbani, Wajd
          Marrie, Ruth Ann
          Bugden, Shawn
          Alessi‐Severini, Silvia
          Bolton, James M.
          Daeninck, Paul
          Leong, Christine
        affil: College of Pharmacy, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg Manitoba, Canada
      sug:
        subj:
          Cannabis Canada
          Prescriptions, Drug Canada
          Health Services Misuse Canada
          Treatment Duration Canada
          Substance Abuse Risk Factors
          Human
          Canada
          Prospective Studies
          Prevalence
          Retrospective Design
          Confidence Intervals
          Adult
          Middle Age
          Socioeconomic Factors
          Fibromyalgia Diagnosis
          Odds Ratio
          Osteoarthritis Diagnosis
          Substance Use Disorders Diagnosis
          Neoplasms Diagnosis
          Persons with Substance Use Disorders Psychosocial Factors
          Adult: 19-44 years
          Middle Aged: 45-64 years
      ab: Background and aims: To estimate prevalence of continuous use (persistence) of prescribed cannabinoid medications for up to 1 year from initial prescription in Manitoba, Canada and predictors of duration of use. Design and setting: A retrospective, population‐based, cohort study using administrative data from the Manitoba Population Research Data Repository located at the Manitoba Centre for Health Policy, Canada. Participants: People without a record of a previous prescription who were prescribed a cannabinoid medication from 1 April 2004 to 1 April 2016 followed for 1 year from the date of first prescription. Measurements Continuous prescribed cannabinoid medication use was defined as use without a gap exceeding 60 days between prescriptions. The primary outcome was prevalence of continuous prescribed cannabinoid medication use for up to 1 year. A secondary outcome was duration of continuous use. Predictors were socio‐demographic characteristics, medical diagnoses and type of cannabinoid medication. Findings Among 5452 new users, 18.1% [95% confidence interval (CI) = 17.08–19.12] were still using cannabinoids at 1 year. Median duration of use was 31 days [interquartile range (IQR) = 25–193]. This was highest for nabilone (33 days, IQR = 25–199) and lowest for nabiximols (20 days, IQR = 7–30). Use was longest among 19–45‐ and 46–64‐year‐old users and those with the highest socio‐economic status. Fibromyalgia [hazard ratio (HR) = 0.89, 95% CI = 0.84–0.95], osteoarthritis (HR = 0.91, 95% CI = 0.82–0.97) and substance use disorder (HR = 0.85, 95% CI = 0.76–0.94) diagnoses were associated with longer use (HR for discontinuation—HR < 1 less discontinuation and longer use). A diagnosis of cancer was associated with shorter use (HR = 2.73, 95% CI = 2.02–3.67). Conclusions: In Manitoba, Canada approximately 18% of people prescribed cannabinoid medication continue using for at least 1 year. Duration of use varies with type of cannabinoid medication, age, socio‐economic status and dagnosis.
      pubtype: Academic Journal
      doctype:
        research
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N